



EZOSE SCIENCES ANNOUNCES APPOINTMENT OF CHIEF OPERATING OFFICER

Glycomics Research Company Names Scott Siegel COO and Expands Scientific Staff

Pine Brook, NJ -- June 25, 2012 -- Ezose Sciences Inc. announced today that Scott A. Siegel, Ph.D., Vice President, Business Development, has been named Chief Operating Officer, a new position at the company.

Dr. Siegel will assume broad responsibility for operations at Ezose, which focuses on glycomics research to identify biomarkers for use in drug development and disease management, and to characterize biotherapeutic glycoforms. He will also continue to lead Business Development. In his new role he will continue to report to Kiyoshi Nagata, Ph.D., Chairman and Chief Executive Officer of Ezose.

“Scott has made Ezose a partner of choice for healthcare companies and academic institutions that seek to realize the promise of glycomics in their R&D programs,” said Dr. Nagata. “At the same time, his talents and energies have already supported various operational activities at Ezose. We look forward to the still broader contributions he will make in his new position.

“The naming of a chief operating officer, together with the other appointments we are announcing today, demonstrates our commitment to helping our partners establish glycomics as a basic tool in their biomedical research.”

Dr. Siegel brings to his role more than 25 years of experience in the biotechnology and pharmaceutical industries. Before joining Ezose in 2009 he was Vice President of Corporate Development for Redpoint Bio, a publically traded biotechnology company. Earlier, he held various positions in New Business Development and Worldwide Strategic Marketing at Johnson & Johnson. He has served in R&D capacities at Phytera, Inc., Centocor, Inc., and Becton Dickinson and Co., and as Adjunct Associate Professor of Microbiology at the University of Pennsylvania. Dr. Siegel is one of the inventors of Remicade® (Infliximab), a therapy for rheumatoid arthritis and other inflammatory disorders.

Dr. Siegel earned his Ph.D. in Biochemistry from the State University of New York, Downstate Medical Center, and completed his postdoctoral studies in the Department of Pharmacology at Yale University School of Medicine.

In other recent appointments, Ezose named:

- Diane McCarthy, Ph.D., Director, Scientific Affairs. Dr. McCarthy was previously a longtime consultant to Ezose. She has held various leadership positions in the biotechnology industry, particularly in the field of proteomics and biomarkers. She earned a doctorate in Biochemistry at the University of Texas at Austin.

- Ezra Jennings, Ph.D., Senior Scientist. Dr. Jennings has developed bioinformatics tools as a consultant to the Whitehead Institute for Biomedical Research and as a senior scientist at a biotech company focusing on diagnostics. He has a doctorate in Biology from the Massachusetts Institute of Technology.
- Joshua Alfaro, Ph.D., Scientist. Dr. Alfaro has conducted various research projects in academic and government laboratories, including development of glycopeptide-enrichment methods. His doctorate in Organic Chemistry was earned at Washington State University

About Glycomics

Glycomics is the study of glycans, the sugar chains that during the biochemical process known as glycosylation become attached to many proteins expressed by human cells. The particular glycans involved may crucially determine the function of the resulting glycoprotein and its role in health and disease.

Glycomics is a natural complement to genomics and proteomics, but it has traditionally been hindered by the lack of practical high-throughput and quantitative technologies. Ezose's proprietary *GlycanMap*® platform addresses this need by combining, in an automated 96-well format, high-throughput glycan enrichment with specialized MALDI-TOF mass spectrometry and custom bioinformatics to both structurally identify and quantitate glycans present in complex biological samples. Such glycans can serve as novel biomarkers to aid in the development of drugs, vaccines, and diagnostic tests, including companion diagnostics. In addition, glycomics holds potential for uncovering new therapeutic targets and mechanisms and for guiding the development and manufacture of glycosylated biologics and biosimilars.

About Ezose

Ezose (pronounced ā-zōse) Sciences Inc., based in Pine Brook, NJ, is dedicated to advancing glycomics to improve scientific understanding and healthcare. Ezose's proprietary *GlycanMap*® technology platform brings a new dimension to biomarker discovery by enabling glycomics research on a scale comparable to that of genomics and proteomics. Ezose offers glycomics capabilities ranging from glycan analytics and biomarker discovery to diagnostic development and commercialization. The company tailors these capabilities to the needs of corporate partners under collaborative R&D and analytical-services agreements.

Established in 2009 as a US company, Ezose is an affiliate of the Diagnostics Division of Shionogi & Co., Ltd., Osaka, Japan.

For more information, visit www.ezose.com.

Forward Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward looking statements whether as a result of new information, future events or otherwise.

Ezose business contact

Scott A. Siegel, Ph.D., Chief Operating Officer

Main: 862-926-1950

Direct: 862-926-1952

Email: info@ezose.com

Ezose media contact

Richard Koenig at Biosyntax LLC

Office: 610-359-1626

Cell: 610-213-0725

Email: rick@biosyntaxllc.com